US Patent Issued to ImmunEdge, The Board of Trustees of the Leland Stanford University on May 26 for "Antibodies that inhibit erythropoietin receptor activation and methods of use thereof to treat cancer" (California Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,637,514, issued on May 26, was assigned to ImmunEdge Inc. (Redwood City, Calif.) and The Board of Trustees of the Leland Stanford University (Stanford, Calif.).

"Antibodies that inhibit erythropoietin receptor activation and methods of use thereof to treat cancer" was invented by Bo Yu (Mountain View, Calif.), Edgar G. Engleman (Atherton, Calif.), Xiangyue Zhang (Sunnyvale, Calif.) and David Kung-Chun Chiu (Mountain View, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides anti-EPOR antibodies, anti-EPO antibodies, and fragments thereof that specifically bind to the hetero-EPOR or homo-EPOR or EPO with high affinity. The...